Sami Corwin
Stock Analyst at William Blair
(0.10)
# 4,434
Out of 5,090 analysts
12
Total ratings
16.67%
Success rate
-20.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Downgrades: Market Perform | n/a | $21.33 | - | 2 | Nov 4, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Outperform | n/a | $7.80 | - | 1 | Aug 20, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $22.26 | - | 1 | Jun 20, 2025 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $65 | $36.38 | +78.67% | 1 | May 28, 2025 | |
| NKTX Nkarta | Downgrades: Market Perform | n/a | $1.80 | - | 1 | May 15, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.22 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $1.41 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $20.28 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $17.87 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $56.88 | +31.86% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $28.13 | - | 1 | May 25, 2023 |
uniQure
Nov 4, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $21.33
Upside: -
Kyverna Therapeutics
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.80
Upside: -
Sarepta Therapeutics
Jun 20, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $22.26
Upside: -
Ultragenyx Pharmaceutical
May 28, 2025
Initiates: Outperform
Price Target: $65
Current: $36.38
Upside: +78.67%
Nkarta
May 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.80
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.22
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.41
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $20.28
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.87
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $56.88
Upside: +31.86%
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $28.13
Upside: -